Page last updated: 2024-08-24
thiazolyl blue and crenolanib
thiazolyl blue has been researched along with crenolanib in 1 studies
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Cortes, J; Galanis, A; Levis, M; Ma, H; Rajkhowa, T; Ramachandran, A; Small, D | 1 |
Trials
1 trial(s) available for thiazolyl blue and crenolanib
Article | Year |
---|---|
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.
Topics: Antineoplastic Agents; Benzimidazoles; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperidines; Point Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Sequence Analysis, DNA; Tetrazolium Salts; Thiazoles; Time Factors | 2014 |